Document is current
Any future updates will be listed below
-
Authors
Nawabi, Jawed http://orcid.org/0000-0002-1137-0643
Kniep, Helge
Elsayed, Sarah
Friedrich, Constanze
Sporns, Peter
Rusche, Thilo
Böhmer, Maik
Morotti, Andrea
Schlunk, Frieder
Dührsen, Lasse
Broocks, Gabriel
Schön, Gerhard
Quandt, Fanny
Thomalla, Götz
Fiehler, Jens
Hanning, Uta
-
Funding
Funding for this research was provided by:
Projekt DEAL
- License Information
-
More Information
Article History
Received: 1 September 2020
Revised: 3 January 2021
Accepted: 12 January 2021
First Online: 6 February 2021
Declarations
:
: - J. Fiehler: Consultant for Acandis, Boehringer Ingelheim, Codman, Microvention, Sequent, Stryker. Speaker for Bayer Healthcare, Bracco, Covidien/ev3, Penumbra, Philips, Siemens. Grants from Bundesministeriums für Wirtschaft und Energie (BMWi), Bundesministerium für Bildung und Forschung (BMBF), Deutsche Forschungsgemeinschaft (DFG), European Union (EU), Covidien, Stryker (THRILL study), Microvention (ERASER study), Philips.- G. Thomalla has received personal fees from Acandis, Bayer, Boehringer Ingelheim, Bristol- Myers Squibb/Pfizer, Daichi Sankyo, Stryker, grants and personal fees from Bayer, grants from the German Research Foundation, Corona Foundation, German Innovation Fund.- All other authors declare that they have no conflict of interest with a company whose product is used in the study or may be affected by its outcome. Please refer to the ICMJE Form for Disclosure of Potential Conflicts of Interest for further details.
